Top-line results from a head-to-head trial comparing Boston Scientific‘s (NYSE:BSX) Ranger drug-coated balloon and Medtronic‘s (NYSE:MDT) In.Pact Admiral DCB found no statistically significant difference in patency rates between the two drug-device products.
The trial is the first of its kind, according to Boston Scientific’s president of peripheral interventions, Jeff Mirviss.
Get the full story at our sister site, Drug Delivery Business News.
The post Boston Scientific’s drug-coated balloon goes up against Medtronic’s DCB in first-of-its-kind trial appeared first on MassDevice.
from MassDevice http://ift.tt/2nxqg6S
Cap comentari:
Publica un comentari a l'entrada